Citations

Clear

6273 citation(s) found for "To, Andrew".

Outcomes of Patients Implanted Using a Left Thoracotomy Technique for a Miniaturized Centrifugal Continuous-Flow Pump
Sileshi, Bantayehu , O’Hara, Brian K., Haglund, Nicholas, Xu, Meng , Deegan, Robert , Stulak, John M., Kushwaha, Sudhir S. , Shaw, Andrew , Maltais, Simon, Davis, Mary Elizabeth

Mayo Clinic

ASAIO Journal | June 26, 2016 | Volume: 62 | Issue: 5 | Pages: 539-544

10.1097/mat.0000000000000407 | PMID 27347709 Get It

As ventricular-assist devices (VADs) are increasingly employed in heart failure management, a leading cause of mortality, new literature is consistently published on less-invasive implantation techniques. Although early perioperative outcomes have been shown to be favorable with minimally invasive left thoracotomy (LT) approaches compared with conventional sternotomy (CS), studies comparing long-term outcomes are lacking. We set out to evaluate long-term follow up between LT and CS approach. In a single center, retrospective review, data on patients with similar demographic profiles were collected. HeartWare (HVAD) implantation was performed by either CS or LT. Analysis was performed on perioperative adverse outcomes, and 6 month postoperative adverse events. Primary objectives of the study included comparative outcomes of morbidity and mortality between both groups at 180 days postimplantation. Eighty-one (n = 81) bridge to transplant (BTT) patients underwent CS or LT HVAD implantation. Perioperative transfusion (p = 0.04) favored the LT cohort compared with CS, with a median of 6 units and 8 units transfused for each group, respectively. No survival difference was observed between both groups at 6 months postimplantation (p = 0.52). Clinical outcomes at an average of 6 month follow up showed no difference in adverse events, including common postoperative VAD complications such as infection and right heart failure. Miniaturization of LVAD size and improvement in technology has allowed expansion of interest in alternative surgical approaches for HVAD implantation. For BTT patients, no difference in early outcome was observed 6 months after implantation using a left LT versus CS technique.
Creatinine–Based and Cystatin C–Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients
Keddis, Mira T. , Amer, Hatem , Voskoboev, Nikolay, Kremers, Walter K. , Rule, Andrew D. , Lieske, John C. , Amer, Hatem , Kremers, Walter K

Mayo Clinic

Clinical Journal of the American Society of Nephrology | June 25, 2016 | Volume: 11 | Issue: 9 | Pages: 1640-1649

10.2215/cjn.11741115 | PMID 27340283 Get It

Background and objectives eGFR equations have been evaluated in kidney transplant recipients with variable performance. We assessed the performance of the Modification of Diet in Renal Disease equation and the Chronic Kidney Disease Epidemiology Collaboration equations on the basis of creatinine, cystatin C, and both (eGFR creatinine-cystatin C) compared with measured GFR by iothalamate clearance and evaluated their non-GFR determinants and associations across 15 cardiovascular risk factors. Design, setting, participants, & measurements A cross-sectional cohort of 1139 kidney transplant recipients >1 year after transplant was analyzed. eGFR bias, precision, and accuracy (percentage of estimates within 30% of measured GFR) were assessed. Interaction of each cardiovascular risk factor with eGFR relative to measured GFR was determined. Results Median measured GFR was 55.0 ml/min per 1.73 m 2 . eGFR creatinine overestimated measured GFR by 3.1% (percentage of estimates within 30% of measured GFR of 80.4%), and eGFR Modification of Diet in Renal Disease underestimated measured GFR by 2.2% (percentage of estimates within 30% of measured GFR of 80.4%). eGFR cystatin C underestimated measured GFR by −13.7% (percentage of estimates within 30% of measured GFR of 77.1%), and eGFR creatinine-cystatin C underestimated measured GFR by −8.1% (percentage of estimates within 30% of measured GFR of 86.5%). Lower measured GFR associated with older age, women, obesity, longer time after transplant, lower HDL, lower hemoglobin, lower albumin, higher triglycerides, higher proteinuria, and an elevated cardiac troponin T level but did not associate with diabetes, smoking, cardiovascular events, pretransplant dialysis, or hemoglobin A1c. These risk factor associations differed for five risk factors with eGFR creatinine, six risk factors for eGFR Modification of Diet in Renal Disease, ten risk factors for eGFR cystatin C, and four risk factors for eGFR creatinine-cystatin C. Conclusions Thus, eGFR creatinine and eGFR creatinine-cystatin C are preferred over eGFR cystatin C in kidney transplant recipients because they are less biased, more accurate, and more consistently reflect the same risk factor associations seen with measured GFR.
Disseminated Mycobacterium chimaera Infection After Cardiothoracic Surgery
Tan, Nicholas Y. , Sampath, Rahul , Saleh, Omar Abu , Jevremović, Dragan , Alniemi, Saba T. , Wengenack, Nancy L. , Sampathkumar, Priya , Badley, Andrew D. , Tweet, Marysia S. , Jevremovic, Dragan , Badley, Andrew D

Mayo Clinic

Open Forum Infectious Diseases | June 17, 2016 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/ofid/ofw131 | PMID 27703994 Get It

Abstract Ten case reports of disseminated Mycobacterium chimaera infections associated with cardiovascular surgery were published from Europe. We report 3 cases of disseminated M chimaera infections with histories of aortic graft and/or valvular surgery within the United States. Two of 3 patients demonstrated ocular involvement, a potentially important clinical finding.
Can Parents Refuse a Potentially Lifesaving Transplant for Severe Combined Immunodeficiency?
Nickels, Andrew S., Myers, Gary Douglas , Joshi, Avni Y. , Sharp, Richard R. , Lantos, John D. , Johnson, Liza‐Marie , Sharp, Richard R

Mayo Clinic

Pediatrics | June 15, 2016 | Volume: 138 | Issue: 1 | Pages: No page available

10.1542/peds.2016-0892 | PMID 27307145 Get It

If untreated, most children with severe combined immunodeficiency disorder (SCID) will die of complications of infection within the first 2 years of life. Early hematopoietic stem cell transplant (HSCT) is the current standard of care for this disease. Although potentially lifesaving, prognosis of HSCT in SCID is variable depending on a number of host and donor factors. Of the survivors, many develop secondary problems such as chronic graft-versus-host disease or even second malignancies. Posttransplant care is complex and requires great effort from parents to adhere to difficult treatment regimens. In this article, we address the difficult ethical question of what to do if parents choose not to have their child with SCID undergo HSCT but prefer palliative care.
Long‐term Outcomes After Osteochondral Allograft: A Systematic Review at Long‐term Follow‐up of 12.3 Years
Assenmacher, Andrew T. , Pareek, Ayoosh , Reardon, Patrick J., Macalena, Jeffrey A. , Krych, Aaron J. , Stuart, Michael J. , Krych, Aaron J , Macalena, Jeffrey A

Mayo Clinic

Arthroscopy | June 15, 2016 | Volume: 32 | Issue: 10 | Pages: 2160-2168

10.1016/j.arthro.2016.04.020 | PMID 27317013 Get It

Purpose To (1) evaluate long‐term outcomes of osteochondral allograft (OCA) with regard to clinical outcome scores, reoperation and failure rates, and (2) examine if certain factors predispose patients to worse outcomes. Methods A comprehensive review was performed with specific inclusion criteria for studies with long‐term outcomes after OCA. Studies reported on patient clinical scores such as Hospital for Special Surgery score, Knee Society Score (knee and function score), and Lysholm score. Reoperation and failure rates were recorded for each study. Modified Coleman Methodology Scores assessed study methodological quality. Results Five studies with a total of 291 patients (55% male, 45% female) and average age of 34.8 years (range, 15 to 69 years) were included. Of all lesions, 67% were on the femoral condyles, 29% on the tibial plateau, and 4% were patellofemoral. All scores (Knee Society Function Score, Knee Society Knee Score, and Lysholm score) have significant mean improvement from preoperative to final follow‐up. The mean postoperative Hospital for Special Surgery score was 84.1. The mean failure rate was 25% at 12.3 years with a reoperation rate of 36%. A total of 72% of the failures were conversion to total (68%) or unicompartmental (4%) knee arthroplasty and 28% involved graft removal, graft fixation, and graft revision. Patellofemoral lesions (83%) had a significantly higher reoperation rate than lesions involving the tibial plateau or the femoral condyles (34%, P = .01). Conclusions Overall, OCA demonstrated significant improvements in clinical outcome scores and good durability with successful outcomes in 75% of the patients at 12.3 years after surgery. Patellofemoral lesions are associated with decreased clinical improvement and more frequent reoperations. The orthopaedic literature is limited by heterogeneity in surgical technique, lesion and patient characteristics, and reporting of nonstandardized outcome measures. Level of Evidence Level IV, systematic review of Level II and IV studies.
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1
Rodriguez, Vilmarie , Kairalla, John A. , Salzer, Wanda L. , Raetz, Elizabeth A. , Loh, Mignon L. , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Asselin, Barbara L. , Carroll, William L. , Dreyer, ZoAnn E., Wood, Brent L. , Burke, Michael J , Devidas, Meenakshi , Winick, Naomi Joan , Hunger, Stephen P. , Dreyer, ZoAnn E. , Loh, Mignon L

Mayo Clinic

Journal of Pediatric Hematology/Oncology | June 14, 2016 | Volume: 38 | Issue: 6 | Pages: 409-417

10.1097/mph.0000000000000589 | PMID 27299599 Get It

AALL08P1 was designed to determine whether biweekly intensified pegaspargase (I-PEG) was feasible and safe in pediatric patients with newly diagnosed high-risk B-precursor lymphoblastic leukemia when given with Children’s Oncology Group hemiaugmented BFM therapy. High-risk average (HR-Avg) patients received standard pegaspargase dosing (6 doses), whereas high-risk high (HR-High) patients received I-PEG biweekly from the start of Consolidation until day 1 of Maintenance. Feasibility and safety were defined in advance as ≥65% of patients tolerating at least 8 doses of I-PEG and 90% requiring ≤49 weeks from day 1 of Consolidation to the initiation of Maintenance. Targeted toxicities included allergic reactions, anaphylaxis, pancreatitis, thrombosis, bleeding, central nervous system events, and sepsis. AALL08P1 enrolled 104 patients; 54 were classified as HR-Avg and 30 as HR-High after completion of induction therapy. Only 53% (16/30) of the HR-High patients received ≥8 total doses of I-PEG and 50% (15/30) took ≤49 weeks from start of Consolidation to the initiation of Maintenance. I-PEG did not significantly increase grade 2 to 5 targeted toxicities. I-PEG was not feasible or safe as defined in AALL08P1. Complete assessment of this regimen was limited due to removal of patients from I-PEG regimen and early closure of the study.
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma
Boddicker, Rebecca L., Razidlo, Gina L. , Dasari, Surendra , Zeng, Yu , Hu, Guangzhen , Knudson, Ryan A., Greipp, Patricia T. , Davila, Jaime , Johnson, Sarah H. , Porcher, Julie C., Smadbeck, James B. , Eckloff, Bruce W., Billadeau, Daniel D. , Kurtin, Paul J. , McNiven, Mark A. , Link, Brian K. , Ansell, Stephen M. , Asmann, Yan W. , Vasmatzis, George , Feldman, Andrew L. , Luchtel, Rebecca A. , Davila, Jaime I, Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Razidlo, Gina L , Greipp, Patricia T , Davila, Jaime I

Mayo Clinic

Blood | June 14, 2016 | Volume: 128 | Issue: 9 | Pages: 1234-1245

10.1182/blood-2016-03-707141 | PMID 27297792 Get It

Abstract Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of T-cell malignancies that generally demonstrate aggressive clinical behavior, often are refractory to standard therapy, and remain significantly understudied. The most common World Health Organization subtype is PTCL, not otherwise specified (NOS), essentially a “wastebasket” category because of inadequate understanding to assign cases to a more specific diagnostic entity. Identification of novel fusion genes has contributed significantly to improving the classification, biologic understanding, and therapeutic targeting of PTCLs. Here, we integrated mate-pair DNA and RNA next-generation sequencing to identify chromosomal rearrangements encoding expressed fusion transcripts in PTCL, NOS. Two of 11 cases had novel fusions involving VAV1, encoding a truncated form of the VAV1 guanine nucleotide exchange factor important in T-cell receptor signaling. Fluorescence in situ hybridization studies identified VAV1 rearrangements in 10 of 148 PTCLs (7%). These were observed exclusively in PTCL, NOS (11%) and anaplastic large cell lymphoma (11%). In vitro, ectopic expression of a VAV1 fusion promoted cell growth and migration in a RAC1-dependent manner. This growth was inhibited by azathioprine, a clinically available RAC1 inhibitor. We also identified novel kinase gene fusions, ITK-FER and IKZF2-ERBB4, as candidate therapeutic targets that show similarities to known recurrent oncogenic ITK-SYK fusions and ERBB4 transcript variants in PTCLs, respectively. Additional novel and potentially clinically relevant fusions also were discovered. Together, these findings identify VAV1 fusions as recurrent and targetable events in PTCLs and highlight the potential for clinical sequencing to guide individualized therapy approaches for this group of aggressive malignancies.
Multiple-level validation identifiesPARK2in the development of lung cancer and chronic obstructive pulmonary disease
Lee, SeungBaek, Deng, Bo , Kim, Jung-Jin, Sun, Zhifu , Wampfler, Jason A. , Cunningham, Julie M. , Wu, Yanhong , Aubry, Marie-Christine, Wendt, Chris H. , Biterman, Peter, Lee, Seung Baek , She, Jun, Kim, JungJin, de Andrade, Mariza, Na, Jie , Lee, SeungBaek , She, Jun , Andrade, Mariza de , Limper, Andrew H. , Yang, Ping , Lou, Zhenkun , Sun, Zhifu , Wendt, Chris H , Lee, Seung Baek

Mayo Clinic

Oncotarget | June 13, 2016 | Volume: 7 | Issue: 28 | Pages: 44211-44223

10.18632/oncotarget.9954 | PMID 27329585 Get It